| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b20bf4e7acb6371d23d34aa573c85847 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate |
2018-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_725bdc7d9157926bacc12304ba9369d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41c3c0da0fb3d6119d9564c99f621763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b643621c5c3280ef12b3317c50020a5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ccce28bac10a9937c23935d5ba519ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42607c180853bd93723ba0b83f49f2b5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9150d910107e6b82ed5f2efca12e2ae |
| publicationDate |
2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10294235-B2 |
| titleOfInvention |
Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof |
| abstract |
The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (LRRK2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal LRRK2 kinase activity. Compounds of the present disclosure can be used to treat disorders including neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy (Hansen's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023076404-A1 |
| priorityDate |
2015-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |